创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

WU Jun, WANG Yazhou, YANG Shengwei, LI Zhiyu. Recent Advances in Inhibitors of Histone Acetyltransferase p300/CBP[J]. Progress in Pharmaceutical Sciences, 2019, 43(2): 118-126.
Citation: WU Jun, WANG Yazhou, YANG Shengwei, LI Zhiyu. Recent Advances in Inhibitors of Histone Acetyltransferase p300/CBP[J]. Progress in Pharmaceutical Sciences, 2019, 43(2): 118-126.

Recent Advances in Inhibitors of Histone Acetyltransferase p300/CBP

  • The p300/CBP family consisting of the highly homologous adenovirus E1A-associated 300 kDa protein (p300) and CREB (cAMP responsive element binding protein) binding protein (CBP) is one of the major members of the histone acetyltransferases families (HAT). Acting as a very important coactivator that can regulate the functions of key transcription regulatory factors, p300/CBP is involved in cell cycle progression as well as cell growth, differentiation and development. Since p300/CBP is also closely related to a variety of tumors, it emerges as a promising target for tumor therapy. This paper reviewed the research progress of p300/CBP inhibitors in order to provide reference for the development of novel selective p300/CBP inhibitors.
  • loading

Catalog

    Turn off MathJax
    Article Contents

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return